Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain

Couñago, Felipe; Martínez-Ballesteros, C.; Artigas, Carlos; Díaz-Gavela, Ana Aurora; Gómez, Luis Leonardo Guerrero; Lillo-García, María Eugenia; Chícharo, Jose Reinaldo; Recio, Manuel; Maldonado, Antonio; Thuissard, Israel; Andreu‐Vázquez, Cristina; Sanz-Rosa, D.; Conde-Moreno, Antonio José; Marcos, Francisco José; García, Sofía Sánchez; Martínez-Salamanca, Juan Ignacio; Carballido-Rodríguez, Joaquín; Hornedo, Javier; Cerro, Elia del

doi:10.1016/j.rpor.2020.03.024

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another trial confirmed the efficacy of mpMRI for local and 68 Ga‐PSMA PET/CT for distant recurrence [11]. Studies (including proPSMA) have shown 68 Ga‐PSMA PET/CT to offer improved treatment selection in both pre‐ and post‐prostatectomy settings [12–15]. Given the evidence favouring modern imaging options and these tests now being publicly funded in Australia, paired mpMRI and 68 Ga‐PSMA PET/CT‐guided therapy may reduce radiation‐related morbidity from standard of care and permit better patient selection for adjuvant/salvage therapies [16].…”

Section: Introductionmentioning

confidence: 99%

Can ⁶⁸Ga‐PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?

et al. 2023

View full text Add to dashboard Cite

ObjectiveTo evaluate the role of multiparametric magnetic resonance imaging (mpMRI) and Gallium‐68 (68Ga)‐prostate‐specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) in guiding salvage therapy for patients with biochemical recurrence (BCR) post‐radical prostatectomy.Patients and MethodsPatients were evaluated with paired mpMRI and 68Ga‐PSMA PET/CT scans for BCR (prostate‐specific antigen [PSA] >0.2 ng/mL). Patient, tumour, PSA and imaging characteristics were analysed with descriptive statistics.ResultsA total of 117 patients underwent paired scans to investigate BCR, of whom 53.0% (62/117) had detectable lesions on initial scans and 47.0% (55/117) did not. Of those without detectable lesions, 8/55 patients proceeded to immediate salvage radiotherapy (sRT) and 47/55 were observed. Of patients with negative imaging who were initially observed, 46.8% (22/47) did not reach threshold for repeat imaging, while 53.2% were rescanned due to rising PSA levels. Of these rescanned patients, 31.9% (15/47) were spared sRT due to proven distant disease, or due to absence of disease on repeat imaging. Of the original 117 patients, 53 (45.3%) were spared early sRT due to absence of disease on imaging or presence of distant disease, while those undergoing delayed sRT still maintained good PSA responses. Of note, patients with high‐risk features who underwent sRT despite negative imaging demonstrated satisfactory PSA responses to sRT. Study limitations include the observational design and absence of cause‐specific or overall survival data.ConclusionOur findings support the use of mpMRI and 68Ga‐PSMA PET/CT in guiding timing and necessity of salvage therapy tailored to detected lesions, with potential to reduce unnecessary sRT‐related morbidity. Larger or randomized trials are warranted to validate this.

show abstract

Section: Introductionmentioning

confidence: 99%

Can ⁶⁸Ga‐PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?

et al. 2023

View full text Add to dashboard Cite

show abstract

Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review

Valle

Shabsovich

Meerleer

et al. 2021

European Urology Oncology

View full text Add to dashboard Cite

The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis

Pozdnyakov

Kulanthaivelu

Ortega

et al. 2022

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain

Cited by 3 publications

References 27 publications

Can ⁶⁸Ga‐PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?

Can ⁶⁸Ga‐PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?

Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review

The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About

Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain

Cited by 3 publications

References 27 publications

Can 68Ga‐PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?

Can 68Ga‐PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?

Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review

The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About

Can ⁶⁸Ga‐PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?

Can ⁶⁸Ga‐PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?